Syed H Jafri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Syed H Jafri has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Glenn Mills
Department of Medicine, Hematology/Oncology, Louisiana State University, 1501 Kings Highway, Shreveport, LA71103, USA
2 shared publications- Run-Hua Shi
North China Electric Power University
2 shared publications - Glenn Mills
Louisiana State Univ Health Sciences Center, Shreveport, LA
1 shared publication - Heather Kleiner-Hancock
Department of Pharmacology, Toxicology & Neuroscience, Louisiana State University, Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130, USA
1 shared publication - Jonathan Glass
Feist-Weiller Cancer Center, Department of Medicine, LSU Health Sciences Center, Shreveport, Louisiana. 1501 Kings Highway, Shreveport, LA 71130, USA
1 shared publication - Misty Prince
Department of Pharmacology, Toxicology and Neuroscience, LSUHSC-S, Shreveport, Louisiana, USA
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 27 March 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 158
Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review
Systemic inflammation has been linked with cancer development, cancer cachexia and poor outcome. Advanced lung cancer inflammation index (ALI) was developed to assess degree of systemic inflammation at the time of diagnosis in metastatic non-small cell lung (NSCLC) cancer patients.
- 27 March 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 158
Top Cited PapersOpen AccessAdvance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review
Systemic inflammation has been linked with cancer development, cancer cachexia and poor outcome. Advanced lung cancer inflammation index (ALI) was developed to assess degree of systemic inflammation at the time of diagnosis in metastatic non-small cell lung (NSCLC) cancer patients.
- 15 February 2013
- Published by Taylor & Francis in Future Oncology
- Vol. 9 (2) , 207-218
Lifestyle Modification in Colorectal Cancer Patients: An Integrative Oncology Approach
Colorectal cancer (CRC) is predominantly a disease of economically developed countries, with many lifestyle-related risk factors proposed that contribute to a higher incidence. These risk factors include obesity, especially visceral fat, lack of physical activity, high consumption of red and processed meat, alcohol and a low intake of dietary fiber. Many population-based studies suggest that a combination of these lifestyle-related risk factors not only increases the incidence of CRC, but also contributes to an increased risk of CRC recurrence after the initial diagnosis. In this article we have reviewed various scientific studies that link lifestyle risk factors with CRC and we propose lifestyle modification as an adjunct intervention to surgery and chemotherapy in patients with early stage and locally advanced CRC.
- 15 February 2013
- Published by Taylor & Francis in Future Oncology
- Vol. 9 (2) , 207-218
Lifestyle Modification in Colorectal Cancer Patients: An Integrative Oncology Approach
Colorectal cancer (CRC) is predominantly a disease of economically developed countries, with many lifestyle-related risk factors proposed that contribute to a higher incidence. These risk factors include obesity, especially visceral fat, lack of physical activity, high consumption of red and processed meat, alcohol and a low intake of dietary fiber. Many population-based studies suggest that a combination of these lifestyle-related risk factors not only increases the incidence of CRC, but also contributes to an increased risk of CRC recurrence after the initial diagnosis. In this article we have reviewed various scientific studies that link lifestyle risk factors with CRC and we propose lifestyle modification as an adjunct intervention to surgery and chemotherapy in patients with early stage and locally advanced CRC.
- 1 January 2011
- Published by Future Medicine Ltd
- Vol. 8 (1) , 23-31
Neoadjuvant chemotherapy in lung cancer
- 1 January 2011
- Published by Future Medicine Ltd
- Vol. 8 (1) , 23-31
Neoadjuvant chemotherapy in lung cancer
- Open Access
- 1 July 2010
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 29 (1) , 87
Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo
Thymoquinone (TQ) is a compound extracted from Black Caraway seeds of Nigella Sativa and is active against various cancers. Cisplatin (CDDP) is the most active chemotherapeutic agent in Lung Cancer. Here we report activity of TQ against non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cell lines alone and in combination with Cisplatin (CDDP).
- 1 July 2010
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 29 (1) , 87
Open AccessThymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo
Thymoquinone (TQ) is a compound extracted from Black Caraway seeds of Nigella Sativa and is active against various cancers. Cisplatin (CDDP) is the most active chemotherapeutic agent in Lung Cancer. Here we report activity of TQ against non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cell lines alone and in combination with Cisplatin (CDDP).